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Abstract
Invariant natural killer T (iNKT) cells are activated during infection, but how they limit microbial growth is unknown in most
cases. We investigated how iNKT cells suppress intracellular Mycobacterium tuberculosis (Mtb) replication. When co-cultured
with infected macrophages, iNKT cell activation, as measured by CD25 upregulation and IFNc production, was primarily
driven by IL-12 and IL-18. In contrast, iNKT cell control of Mtb growth was CD1d-dependent, and did not require IL-12, IL-18,
or IFNc. This demonstrated that conventional activation markers did not correlate with iNKT cell effector function during
Mtb infection. iNKT cell control of Mtb replication was also independent of TNF and cell-mediated cytotoxicity. By
dissociating cytokine-driven activation and CD1d-restricted effector function, we uncovered a novel mediator of iNKT cell
antimicrobial activity: GM-CSF. iNKT cells produced GM-CSF in vitro and in vivo in a CD1d-dependent manner during Mtb
infection, and GM-CSF was both necessary and sufficient to control Mtb growth. Here, we have identified GM-CSF
production as a novel iNKT cell antimicrobial effector function and uncovered a potential role for GM-CSF in T cell immunity
against Mtb.
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Introduction
CD1 restricted T cells were first proposed to have a role in
antimicrobial immunity based on the observations that CD42CD82
(DN) T cells restricted by group 1 CD1 (CD1a, CD1b, and CD1c)
recognized unique and complex lipids from the Mtb cell wall [1,2].
Similarly, invariant natural killer T (iNKT) cell antimicrobial function
was originally based on the recognition of microbial lipid or glycolipid
molecules presented by the MHC-like molecule CD1d. iNKT cells
are now recognized to influence many different immunological
conditions including autoimmune disease, asthma and allergy, anti-
tumor response, graft-versus-host disease, and infection [3].
There are several pathways by which iNKT cells can be activated.
Classically, high affinity antigens that are potent agonists, typified by
the synthetic lipid a-galactosylceramide (aGalCer), trigger TCR
activation in a CD1d-dependent manner. Several infectious agents
produce microbial lipids that are presented on CD1d and recognized
by iNKT cells including Borrelia burgdorferi and Sphingomonas capsulata
[4,5,6]. Activation can also occur when iNKT cells recognize a weak
lower affinity self or microbial ligand, insufficient by itself to induce
activation, in the context of costimulatory signals. This mode of
activation has been shown for pathogens, such as Salmonella
typhimurium, viruses such as Influenza A, and fungi such as Aspergillus
fumigatus [7,8,9]. There is strong evidence that a major driver of this
type of iNKT cell activation is IL-12, which is produced when
microbial danger signals stimulate pattern recognition receptors such
as Toll-like receptors (TLRs) or dectin-1 [7,9,10].
One of the remaining unanswered questions in iNKT cell
biology is what specific role these cells have during infection and
whether their activation by different pathways leads to the
expression of diverse functions. To address the role of iNKT cells
during infection, many of these studies have used mouse models
that lack iNKT cells (Ja182/2, CD1d2/2) or administered
aGalCer, a potent activator of iNKT cells. While this strategy
has been useful for determining whether iNKT cells are required
for host resistance, and for revealing potential antimicrobial
effector functions induced after strong activation, much less is
known about the physiological role of iNKT cells during infection.
Tracking iNKT cell function in vivo has relied extensively on
CD69 upregulation and IFNc production. Interestingly, in the
absence of exogenous aGalCer treatment, there is little evidence
that IFNc production by iNKT cells is protective during infection
[11]. Given that iNKT cells are capable of producing a variety of
different cytokines and chemokines including IL-4, IL-10, IL-17,
TNF, GM-CSF, MIP-1a, MIP-1b as well as having immuno-
modulatory effects via expression of CD40 and other costimula-
tory ligands [12], it is surprising that it is still unknown for most
infections whether iNKT cells have a direct antimicrobial role.
Only in select cases have protective mechanisms been defined. For
example, iNKT cells are important for neutrophil recruitment to
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the lung during Pseudomonas infection [13] and IFNc is required for
protection by iNKT cells against Streptococcus pneumoniae, although
this could represent a direct or indirect effect [11].
There are several lines of evidence that activated iNKT cells
enhance host resistance to Mtb. Administration of aGalCer, which
activates iNKT cells in vivo, significantly prolongs the survival of
susceptible mouse strains following Mtb infection and this effect is
synergistic with antibiotics [14,15]. aGalCer activates human iNKT
cells to lyse Mtb-infected macrophages and kill intracellular bacteria
[16]. Even BCG vaccination is more effective when it is conjugated
with aGalCer [17]. Although aGalCer is used as a pharmacological
activator of iNKT cells in this context, it is not required. iNKT cells
cultured with Mtb-infected primary macrophages stimulate antimi-
crobial activity that restricts bacterial growth and adoptive transfer
of iNKT cells limits bacterial growth in vivo [18]. Finally, several
clinical studies find that a decrease of iNKT cells in the periphery is
a marker of active disease compared to latent infection or healthy
controls [19,20,21]. Despite these findings of iNKT cell activation
leading to enhanced control, iNKT cells are dispensable in the
murine model of chronic tuberculosis infection [22,23,24,25].
Our model, in which iNKT cells activate infected macrophages
to control Mtb infection in the absence of exogenous stimulation
(e.g., aGalCer), provided a unique opportunity to define the direct
effector functions of iNKT cells. This model allowed us to study
the interaction between iNKT cells and Mtb-infected macrophag-
es and provided the opportunity to perturb specific signaling and
effector pathways and then measure subsequent changes in
bacterial control. Greater insight into the effector function of
iNKT cells during Mtb infection could lead to novel therapeutic
approaches for augmenting their antimicrobial capacity and
boosting the host immune response during infection [14,15].
Here we report that iNKT cells upregulated activation markers
and produced IFNc during Mtb infection in vitro and these
markers of activation were driven largely by IL-12 and IL-18.
Blocking these cytokine signals almost completely inhibited IFNc
production, but surprisingly had little effect on the ability of iNKT
cells to control Mtb growth. In contrast, the antimicrobial function
of iNKT cells required CD1d signaling and was mediated by a
soluble factor, GM-CSF. Blocking GM-CSF abrogated restriction
of bacterial growth by iNKT cells and GM-CSF was sufficient to
inhibit mycobacterial growth in vitro. We identified GM-CSF as
an antimycobacterial effector molecule produced by iNKT cells
with the ability to suppress Mtb infection.
Results
iNKT cells are activated by Mtb-infected macrophages
CD69 and CD25, both classic T cell activation markers, as well
as IFNc production, were chosen to track the activation of iNKT
cells by Mtb-infected macrophages. Primary mouse iNKT cell
lines were co-cultured with thioglycollate-elicited peritoneal
macrophages infected with increasing multiplicity of infection
(MOI) of H37Rv, a virulent strain of Mtb. After 24 hours, iNKT
cells cultured with Mtb-infected macrophages expressed higher
levels of CD69 and CD25 and produced more IFNc compared to
iNKT cells cultured with uninfected macrophages (Figures 1A and
1B). A similar activation pattern was observed when hepatic
mononuclear cells (HMNC), a source of primary uncultured
iNKT cells, were used (Figure S1A) or when iNKT cells were
cultured with H37Rv-infected bone marrow derived macrophages
(BMDM) (Figure S1B). These data indicate that iNKT cells
become activated after stimulation with Mtb-infected APCs.
iNKT cell activation by Mtb-infected macrophages
requires a combination of cytokine and CD1d-dependent
signals
Infection by various microbes including Salmonella, Aspergillus,
and E. coli LPS, induce iNKT cell activation by a combination of
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Figure 1. iNKT cells are activated by Mtb-infected mw. (A) iNKT
cells were cultured either alone, with uninfected thioglycollate-elicited
peritoneal mw, or H37Rv-infected mw for 24 hours. Cells were stained
for CD69 and CD25 and mw were distinguished from iNKT cells by F4/80
staining. (B) Fold change in CD69 and CD25 MFI on iNKT cells cultured
with uninfected or H37Rv-infected mw compared to iNKT cells alone.
Supernatant was harvested at 24 hours and IFNc measured by ELISA.
Error bars indicate mean 6 SEM. *P,.05, **P,.01, ***P,.001. (One-way
ANOVA with Dunnet’s post-test, compared to iNKT cells alone). Data are
representative of eight independent experiments. Mw, macrophage; UI,
uninfected; , MOI titration, 1.5:1, 3:1, 6:1.
doi:10.1371/journal.ppat.1003805.g001
Author Summary
Mycobacterium tuberculosis (Mtb) is the cause of tubercu-
losis, a leading cause of sickness and death worldwide.
Although much is known about CD4+ and CD8+ T cell
responses to Mtb, the role of other T cell subsets is poorly
understood. Invariant natural killer T (iNKT) cells are innate
lymphocytes that express a semi-invariant T cell receptor
and recognize lipid antigens presented by CD1d. Although
iNKT cells participate in the immune response to many
different pathogens, little is known about how iNKT cells
directly kill microbes. We previously showed that when co-
cultured with Mtb-infected macrophages, iNKT cells inhibit
intracellular Mtb replication. Now, we used this model to
dissociate the signals that induce iNKT cell activation
markers including IFNc production, from the signals that
activate iNKT cell antimicrobial activity. This allowed us to
uncover a novel antimicrobial effector function produced
by iNKT cells: GM-CSF. GM-CSF is essential for immunity to
Mtb, but its role has never been defined. This study is the
first report to demonstrate a protective function of GM-
CSF production by any T cell subset during Mtb infection. T
cell production of GM-CSF should be considered as a
potential mechanism of antimicrobial immunity.
iNKT Cell Production of GM-CSF Controls Mtb
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IL-12, IL-18, and/or TCR stimulation through interaction with
CD1d [7,9,10,26]. To determine whether these signals were
required for the activation of iNKT cells by Mtb-infected
macrophages, we added neutralizing antibodies to cell co-cultures
and measured iNKT cell activation after 24 hours. We found that
CD25 and IFNc were inhibited to varying degrees by blockade of
the activating signals (Figures 2A and 2B). CD69 expression was
more variable and blocking antibodies had little effect on its
expression (data not shown). Blocking cytokine signals (IL-12p40,
IL-18) had a greater inhibitory effect on the markers than blocking
the TCR-CD1d interaction. For example, anti-IL-12p40 reduced
CD25 surface expression by 45.763.3%, and inhibited IFNc
production nearly completely (91.464.4%) (mean 6 SEM, n = 4
experiments) (Figures 2A and 2B). In contrast, anti-CD1d had no
effect on CD25 expression and only a modest effect on IFNc
production (37.566.4% reduction) (mean 6 SEM, n = 3–4
experiments). The failure of anti-CD1d to block iNKT cell
activation was not due to a problem with the experimental
conditions since anti-CD1d blocked induction of CD25 and
abrogated IFNc production after a-GalCer stimulation of iNKT
cells (Figures 2A and 2B). To verify that cytokines were driving
iNKT cell activation, iNKT cells were cultured with MyD882/2
macrophages, which do not produce IL-12 after H37Rv infection
[27] (Figure 2C). When co-cultured with Mtb-infected MyD882/2
macrophages, iNKT cells did not upregulate CD25 or secrete
IFNc. These results indicated that IL-12 and IL-18 produced by
macrophages during Mtb infection drove the activation of iNKT
cells as measured by induction of CD25 surface expression and
IFNc production. Thus, these conventional markers of iNKT cell
activation were not reliable indicators of CD1d-dependent TCR-
mediated signaling during Mtb infection.
Control of intracellular Mtb growth by iNKT cells requires
CD1d but not IL-12 and IL-18
As shown previously, iNKT cells cultured with H37Rv-infected
macrophages reduced intracellular bacterial growth over a 5 day
infection [18] (Figure 3A). We used this co-culture model to
evaluate how the different activation signals affected iNKT cell
antimicrobial activity.
We first tested the requirement for IL-12 and IL-18 signaling.
The addition of anti-IL-12p40 and/or anti-IL-18 blocking
antibodies to co-cultures of iNKT cells and H37Rv-infected WT
macrophages did not affect the ability of iNKT cells to inhibit
bacterial growth (Figure 3A). We confirmed this result using
MyD882/2 macrophages, which did not induce upregulation of
CD25 or IFNc by iNKT cells (Figure 2C). iNKT cells were able to
inhibit bacterial growth in H37Rv-infected MyD882/2 macro-
phages (Figure 3B). These findings were unexpected because they
suggested that the traditional markers of activation did not
correctly predict iNKT cell antimycobacterial function.
We next addressed whether CD1d expression by the infected
macrophages was required. iNKT cells were able to limit
intracellular bacterial growth only if the infected macrophages
expressed CD1d (Figure 3C). Normalizing the bacterial growth in
each experiment allowed us to determine the requirement for
CD1d across multiple experiments (see Experimental Procedures
for details). When Mtb growth inhibition by iNKT cells in WT
and CD1d2/2 macrophages were compared in this manner,
iNKT cells suppressed growth of Mtb in WT macrophages
significantly more than in CD1d2/2 macrophages (73.164.7%
CFU reduction vs. 31.569.3%) (mean6 SEM, n = 6 experiments,
p = 0.0002) (Figure 3D). To confirm the dependence on CD1d for
bacterial control by iNKT cells, and to show that the culture
conditions of the primary cell lines had not significantly altered the
effector functions of the iNKT cells, we repeated this experiment
using HMNC as a source of primary uncultured iNKT cells. We
found that HMNCs also required CD1d signaling for inhibition of
bacterial growth (Figure 3E).
Since CD1d expression by macrophages was required to elicit
optimal iNKT cell effector function, we considered whether Mtb
infection altered the CD1d surface expression on macrophages.
After 24 hours, H37Rv infection led to a modest increase in CD1d
surface expression on macrophages (1.560.1 fold change) (mean
6 SEM, n = 13 experiments, p,0.0001) (Figure 3F). Co-culture
with iNKT cells led to a slight increase in CD1d expression during
H37Rv infection (1.960.1 fold change) (mean 6 SEM, n = 22
experiments, p,0.0001) (Figure 3F). These increases were
averages for the bulk culture and may have underestimated the
increase for individually infected macrophages, because not every
macrophage was infected.
These results indicated that the cytokines (IL-12, IL-18) that
drive expression of CD25 and IFNc production were not required
to stimulate iNKT cell antimycobacterial effector functions. In
contrast, CD1d expression, which played only a small role in
stimulating IFNc production, was required for iNKT cell
mediated control of intracellular Mtb growth. The dissociation
between standard measurements of iNKT cell activation from
iNKT cell effector function in response to Mtb infection was
unexpected.
iNKT cells exhibit an antimycobacterial function
independent of IFNc
Since IL-12 and IL-18 blockade largely inhibited IFNc
production but had little impact on CFU control, we considered
whether iNKT cell antimicrobial effector function was indepen-
dent of IFNc. To test this, we derived an IFNc2/2 iNKT cell line.
When IFNc2/2 iNKT cells were added to H37Rv-infected
macrophages, they inhibited bacterial growth similar to WT iNKT
cells (Figure 4A). Over multiple experiments, WT and IFNc2/2
iNKT cells reduced bacteria growth similarly by d5 by 60.064.7%
versus 60.164.0%, respectively (mean 6 SEM, n = 13 experi-
ments, p = NS) (Figure S2). A similar result was found by d7 post-
infection (Figure S2).
IFNc plays an important antimicrobial role during Mtb
infection. To be certain that iNKT cells were controlling bacterial
growth independently of IFNc signaling, WT and IFNc2/2 iNKT
cells were cultured with H37Rv-infected IFNcR2/2 macrophages.
The iNKT cells still limited bacterial growth by d5 in these cells
(Figure 4B). We also examined whether iNKT cells controlled Mtb
growth through nitric oxide, an important mediator of anti-
mycobacterial immunity produced during infection by IFNc
stimulation of the enzyme inducible nitric oxide synthase (iNOS)
[28]. Neither IFNc nor nitrite, a stable breakdown product of
nitric oxide, were detected after addition of IFNc2/2 iNKT cells,
while both were detected when WT iNKT cells were present
(Figure 4C). Furthermore, naı¨ve splenocytes (as a source of iNKT
cells [18]) inhibited bacterial replication similarly in WT,
IFNcR2/2, and iNOS2/2 macrophages (data not shown). We
next tested whether the IFNc2/2 iNKT cells also required CD1d
to mediate their antimicrobial effector function. Similar to WT
iNKT cells, IFNc2/2 iNKT cells inhibited growth of Mtb in WT
macrophages significantly more than in CD1d2/2 macrophages
by 73.367.2% versus 34.4610.6% (mean 6 SEM, n = 5
experiments, p = 0.0043) (Figure 4D). These data demonstrated
that iNKT cells were capable of controlling Mtb growth
independently of IFNc and nitric oxide and that the IFNc-
independent effector function required CD1d-mediated activation.
iNKT Cell Production of GM-CSF Controls Mtb
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Figure 2. Production of IL-12 and IL-18 by Mtb-infected mw induce traditional markers of iNKT cell activation. (A) iNKT cells were
cultured either alone, with uninfected mw, H37Rv-infected mw, or aGalCer-loaded mw for 24 hours in the presence of blocking antibodies against IL-
12p40 (20 mg/ml), IL-18 (10 mg/ml), CD1d (20 mg/ml), or respective isotype controls. Cells were stained for CD25 and mw were distinguished from
iNKT Cell Production of GM-CSF Controls Mtb
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iNKT cell antimicrobial function is independent of
cytolytic activity and TNF
Human iNKT cells stimulated with aGalCer were shown to
control Mtb infection in human monocyte-derived macrophages
through granulysin-mediated cytolytic activity [16]. Based on this
finding, we determined whether iNKT cells, in the absence of
additional stimulation, inhibited Mtb growth through cytolytic
activity. To block the major pathways of cytolysis, we added
Perforin2/2 (Pfn2/2) iNKT cells to H37Rv-infected WT macro-
phages (Figure 5A). In addition, we added either WT or IFNc2/2
iNKT cells by F4/80 staining. Supernatant was harvested at 24 hours and IFNc measured by ELISA. (B) % reduction calculated as 100*[(iNKTH37Rv-
mw2iNKTalone)2(iNKTAb+H37Rv-mw2iNKTalone)]/(iNKTH37Rv-mw2iNKTalone). Conditions with aGalCer stimulation calculated similarly. (C) iNKT cells were
cultured with uninfected or H37Rv-infected WT or MyD882/2 mw for 24 hours. Cells were stained for CD25 and mw were distinguished from iNKT
cells by F4/80 staining. Supernatant was harvested at 24 hours and IFNc and IL-12p40 measured by ELISA. Error bars indicate mean6 SEM. **P,0.01
compared to isotype control. (One-way ANOVA with Dunnet’s post-test). #P,0.05, ##P,0.01 compared to isotype control (data not shown)
(unpaired Student’s t-test). +P,0.05, ++P,0.01, +++P,0.001 (unpaired Student’s t-test). Data are representative of, or compiled from, (A,B) three
(anti-CD1d), four (anti-IL-12), two (anti-IL-18) and (C) two independent experiments.
doi:10.1371/journal.ppat.1003805.g002
Figure 3. iNKT cell mediated control is CD1d-dependent but does not require IL-12 or IL-18. (A) Colony forming unit (CFU) assay
measuring Mtb bacterial growth in H37Rv-infected WT mw on d1 and d5 post-infection. iNKT cells, anti-IL-12p40, anti-IL-18 blocking or isotype
control antibodies were added on d1 after infection. (B) CFU assay d1 and d5 post-infection for H37Rv-infected MyD882/2 mw with iNKT cells added
on d1. (C, E) CFU assay d1 and d5 post-infection for H37Rv-infected WT and CD1d2/2 mw with iNKT cells added on d1 at a ratio of 1:1 (C) or HMNC at
a ratio of 3:1 (E). (D) Compiled data from 6 independent experiments as described in (C). (F) H37Rv-infected mw after 24 hours. CD1d MFI fold change
over uninfected mw either without or with iNKT cells. Error bars indicate mean 6 SEM. *P,0.05, **P,0.01, ***P,0.001 (One-way ANOVA with
Dunnet’s post-test, compared to d5 untreated mw). +++P,.001 (unpaired Student’s t-test). Data are representative of two (A, B) six (C, D), and one (E)
independent experiment(s) with three or more replicates, or more than 12 independent experiments (F).
doi:10.1371/journal.ppat.1003805.g003
iNKT Cell Production of GM-CSF Controls Mtb
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iNKT cells to Fas2/2 macrophages (Figure 5B). Under these
conditions, iNKT cells still significantly suppressed Mtb growth in
macrophages. To eliminate the possibility of redundancy between
cytolytic pathways, Pfn2/2 iNKT cells were added to H37Rv-
infected Fas2/2 macrophages, and despite elimination of both of
the dominant CTL pathways, iNKT cells were still able to
significantly inhibit bacterial growth (data not shown). These data
show that the major cytolytic pathways were not required for
iNKT cell antimicrobial function in this system.
We also took an alternative approach to inhibit cytolytic activity
by blocking an important downstream effector of cytolytic activity,
caspase-3. Using a specific peptide inhibitor to inhibit caspase-3
activity and apoptosis in target cells, we found that addition of
caspase-3 inhibitor to co-cultures of IFNc2/2 iNKT cells and
H37Rv-infected macrophages, at concentrations that block
apoptosis of infected macrophages [29], did not affect the ability
of IFNc2/2 iNKT cells to inhibit bacterial growth (Figure 5C).
TNF plays an important antimicrobial role during Mtb
infection [30] and we detected TNF, albeit at low levels, in our
co-culture system (data not shown). Therefore, we used TNFR1/
22/2 macrophages, which lack both TNF receptors, to test
whether TNF signaling was required for iNKT cell control of Mtb.
Both WT and IFNc2/2 iNKT cells inhibited bacterial growth
when cultured with H37Rv-infected TNFR1/22/2 macrophages,
indicating that TNF did not mediate the antimicrobial effector
function of IFNc2/2 iNKT cells (Figure 5D). Finally, based on the
newly appreciated role of IL-1b in limiting growth of Mtb in
macrophages [31,32], we determined whether IL-1b mediated
iNKT cell control of bacterial growth. IFNc2/2 iNKT cells
cultured with IL-1R2/2 macrophages controlled Mtb growth,
ruling out a role for IL-1b signaling (data not shown).
These data showed that iNKT cells controlled Mtb growth
independently of cytolytic activity and cytokines previously identified
as antimycobacterial, TNF and IL-1b. They suggested that iNKT
cells limit bacterial growth through a non-classical effector function.
iNKT cells secrete a soluble factor with antimicrobial
properties
We next determined whether the antimicrobial activity was a
soluble factor or cell contact dependent. Using a transwell system,
Figure 4. iNKT cell mediated control is independent of IFNc. (A)
CFU for H37Rv-infected WT mw with WT and IFNc2/2 iNKT cells added
on d1 post-infection. CFU were measured on d0 (mw alone) and on d1,
d3, d5 and d7 post-infection. (B) CFU assay d1 and d5 post-infection for
H37Rv-infected IFNcR2/2 mw with WT and IFNc2/2 iNKT cells added on
d1. (C) IFNc and nitrite, a stable breakdown product of NO2, measured
for H37Rv-infected WT mw with WT and IFNc2/2 iNKT cells added on d1
post-infection. (D) Compiled data from 5 independent experiments of
the CFU assay d1 and d5 post-infection with H37Rv-infected WT and
CD1d2/2 mw with IFNc2/2 iNKT cells added on d1. Error bars indicate
mean 6 SEM. *P,0.05, **P,0.01, ***P,.001 (One-way ANOVA with
Dunnet’s post-test, compared to d3, d5, or d7 untreated mw). ++P,.01
(Unpaired Student’s t-test). Data are representative of or cumulative
from 13 (d5) and four (d7) (A), two (B) three (C), or four (D) independent
experiments with three or more replicates.
doi:10.1371/journal.ppat.1003805.g004
Figure 5. IFNc-independent antimicrobial effector function of
iNKT cells is independent of cytolytic activity. (A–D) CFU assay
d1, d5, and/or d7 post-infection with H37Rv-infected WT mw (A, C),
Fas2/2 mw (B), or TNFR1/22/2 mw (D) with WT iNKT cells (A, B, D),
IFNc2/2 iNKT cells (B–D), or Prf2/2 iNKT cells (A) added on d1 post
infection at a 1:1 ratio. (C) H37Rv-infected mw were treated with 0.1–
10 mM of caspase-3 inhibitor peptide (Z-DEVD-FMK) 2 hours prior to
addition of iNKT cells. Error bars indicate mean 6 SEM. *P,0.05,
**P,0.01 (One-way ANOVA with Dunnet’s post-test, compared to d5 or
d7 untreated mw.) Data are representative of three (A, C, D) or two (B)
independent experiments with three or more replicates.
doi:10.1371/journal.ppat.1003805.g005
iNKT Cell Production of GM-CSF Controls Mtb
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we found that both WT and IFNc2/2 iNKT cells placed in trans
from H37Rv-infected macrophages were able to suppress Mtb
growth (Figure 6). Importantly, this effect was only observed if the
iNKT cells were in contact with other macrophages in the
transwell, but not when the iNKT cells were cultured alone. This
was consistent with our observation that induction of the iNKT
cell effector function required CD1d signaling via macrophage
contact. The finding that contact between iNKT cells and
uninfected macrophages was sufficient to induce the antimicrobial
activity raised the possibility that a mediator secreted by infected
macrophages (e.g., in trans) augmented iNKT cell activation,
either by increasing macrophage CD1d expression or by
costimulating iNKT cell activation. Most importantly, this
experiment confirmed that iNKT cells required cell contact and
CD1d expression for their activation, and indicated that their
antimicrobial activity was mediated by a soluble factor.
We also found that aGalCer stimulation of IFNc2/2 iNKT
cells cultured in trans boosted their ability to control bacterial
growth (data not shown). Furthermore, conditioned media
produced from IFNc2/2 iNKT cells stimulated with aGalCer-
loaded WT but not CD1d2/2 macrophages stimulated bacterial
control when added to macrophages (Figure S3). We then used
conditioned media samples derived from IFNc2/2 iNKT cells
stimulated by unloaded or aGalCer-loaded WT or CD1d2/2
macrophages for screening purposes. These samples were size
fractionated at 10 kDa and 50 kDa MW cutoffs. We identified
several cytokines present at high levels only in the fractions that
had antimicrobial activity: GM-CSF, TNF, and IL-4 (Figure S3).
Since TNF had been previously eliminated and IL-4 is not known
to enhance bacterial control [33], we investigated whether iNKT
cells produced GM-CSF after co-culture with Mtb-infected
macrophages and whether it had antimycobacterial activity.
iNKT cells produce GM-CSF during Mtb infection in a
CD1d-dependent manner and it is critical for controlling
Mtb growth
We detected GM-CSF production 24 hours after co-culture of
both WT and IFNc2/2 iNKT cells with H37Rv-infected
macrophages (Figure 7A, Figure S4). Because we had already
established that the IFNc-independent antimicrobial function was
CD1d-dependent, we tested whether GM-CSF production by
iNKT cells required CD1d expression. We found that IFNc2/2
iNKT cells produced significantly more GM-CSF when cultured
with Mtb-infected WT macrophages than with Mtb-infected
CD1d2/2 macrophages; however, some GM-CSF was produced
even in the absence of CD1d, especially at higher Mtb MOI
(Figure 7B).
To determine if GM-CSF was required for iNKT cell-mediated
control in vitro, we added anti-GM-CSF blocking antibodies to the
co-culture of IFNc2/2 iNKT cells and Mtb-infected macrophag-
es. GM-CSF blockade impaired bacterial control by IFNc2/2
iNKT cells leading to a significant increase in CFU compared to
both an isotype control and untreated conditions (Figure 7C). This
suggested that GM-CSF was required for iNKT cell mediated
control of Mtb infection in this model. When we added anti-GM-
CSF blocking antibodies to co-cultures of WT iNKT cells and
Mtb-infected macrophages, we observed a modest decrease in
bacterial inhibition by WT iNKT cells in the GM-CSF blockade
condition compared to untreated or isotype control, although it
was not significant (Figure S5). These results suggest that either the
antimicrobial functions of GM-CSF are less crucial in the presence
of IFNc or that there is redundancy in the antimicrobial
mechanisms of these two cytokines.
To determine if this iNKT cell effector pathway was also relevant
for human cells, we tested the human iNKT cell clone J3N.5. The
iNKT cells produced significantly more GM-CSF after co-culture
with H37Rv-infected U937 cells, a human monocytic line, than with
uninfected U937 cells and this was inhibited by addition of an anti-
CD1d blocking antibody (Figure 7D). J3N.5 also produced IFNc in
response to H37Rv-infected U937 cells, and this was similarly
inhibited by an anti-CD1d blocking antibody (data not shown). Next,
we determined whether iNKT cells produced GM-CSF during
aerosol infection in vivo. We isolated cells from the lungs of mice
infected with virulent Mtb at serial time points after infection.
Pulmonary iNKT cells were identified by TCRb and CD1d
tetramer staining and their production of GM-CSF and IFNc was
assessed by intracellular cytokine staining (ICS) directly ex vivo
without further stimulation. The frequency of iNKT cells in the lung
did not change greatly over the course of infection, although the total
number of iNKT cells increased in parallel with the overall increase
in T cell recruitment to the lung (Figure S6A and S6B). Similar to
our in vitro observations, CD69 expression increased on iNKT cells
in the lung over the course of infection (Figure S6C). A small
percentage of iNKT cells in the lungs of naive mice secreted GM-
CSF. By two weeks post-infection, there was an increase in both the
percentage and absolute number of iNKT cells producing GM-CSF;
this was not the case for IFNc (Figure 7E and 7F). At all time points
examined post-infection, a significantly greater percentage of iNKT
cells in the lung produced GM-CSF than IFNc. For example, at
week 2, 11.061.3% iNKT cells were GM-CSF+ compared to
1.060.3% IFNc+ iNKT cells (mean 6 SEM, p,0.0001). These
data demonstrated that iNKT cells are an early source of GM-CSF
in the lung during Mtb infection and underscored our in vitro
observation that GM-CSF and IFNc production by iNKT cells are
regulated differently during Mtb infection.
In order to evaluate the role of CD1d signaling in the
production of GM-CSF by iNKT cells in vivo, we used an
adoptive transfer model, in which fluorescently-labeled iNKT cells
were injected iv into Mtb-infected WT or CD1d2/2 recipients.
Downregulation of the iNKT cell TCR usually limits the ability to
detect iNKT cells in vivo. This transfer model allowed monitoring
of iNKT cells in vivo without the need for CD1d tetramer staining.
Figure 6. The antimicrobial effector function of iNKT cells is a
soluble factor. Transwell CFU assay for H37Rv-infected WT mw in a 24-
well plate with either WT or IFNc2/2 iNKT cells added directly (cis) or
0.4 mm transwell inserts with WT or IFNc2/2 iNKT cells in the presence
of uninfected WT mw (trans) added on d1. Error bars indicate mean 6
SEM. *P,0.05, **P,0.01 (One-way ANOVA with Dunnet’s post-test,
compared to d5 untreated mw.) Data are representative of two
independent experiments with four replicates each.
doi:10.1371/journal.ppat.1003805.g006
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We detected significantly less GM-CSF and IFNc production by
iNKT cells transferred into Mtb-infected CD1d2/2 hosts com-
pared to WT hosts, while CD69 expression was induced on iNKT
cells transferred into both WT and CD1d2/2 recipients
(Figure 7G). Interestingly, we observed a strong CD1d-dependent
IFNc response by the transferred iNKT cells, which we did not
detect in the intact mice (Figure 7E and 7F). The transferred
iNKT cells were likely to have a stronger response and a lower
threshold for activation due to their prior stimulation in vitro.
There is recent data, discussed below, that epigenetic modifica-
tions at the IFNG locus of iNKT cells may explain why IFNc is
only detected after priming by a strong stimulus [34]. The
observation that the in vivo IFNc response was almost entirely
CD1d-dependent suggests that our in vitro infection model may be
over-estimating the effect of cytokine-driven stimulation. This
experiment also confirmed our in vitro results that activation
marker expression and effector functions could be elicited by
distinct activating pathways in iNKT cells.
These data showed that both murine and human iNKT cells
produced GM-CSF upon recognition of Mtb infection in a
CD1d-dependent manner and GM-CSF was a critical component
of iNKT cell antimycobacterial function in vitro.
GM-CSF is sufficient to inhibit Mtb growth
We next determined whether GM-CSF alone was sufficient to
mediate control of Mtb growth. In a dose-dependent manner,
recombinant GM-CSF added to infected macrophages was
sufficient to inhibit Mtb growth (Figure 8). Recombinant GM-
CSF has also previously been reported to inhibit the growth of
mycobacterium in human monocyte-derived macrophages
(MDM) [35,36,37]. The data showed that GM-CSF was sufficient
to inhibit bacterial growth in murine macrophages.
Discussion
We find that iNKT cells cultured with Mtb-infected macro-
phages inhibit intracellular bacterial growth [18]. This is the only
model of which we are aware that allows investigation of the direct
antimicrobial effector function of iNKT cells. In the presence of
Mtb-infected macrophages, iNKT cells became activated and
Figure 7. iNKT cells produce GM-CSF during Mtb infection in a CD1d-dependent manner and it is critical for controlling Mtb
growth. (A, B) IFNc2/2 iNKT cells added to uninfected or H37Rv-infected WT (A, B) and CD1d2/2 mw (B). Murine GM-CSF measured in supernatant
harvested after 24 hours. (C) % CFU reduction calculated from CFU assays for H37Rv-infected WT mw with IFNc2/2 iNKT cells added on d1 in the
presence of anti-GM-CSF blocking antibody (10–50 mg/ml) or isotype control. (D) J3N.5 human iNKT cell clone added to uninfected or H37Rv-infected
U937 cells in the presence of anti-human-CD1d blocking antibody or isotype control. Human GM-CSF measured in supernatant harvested after
24 hours. (E, F) Lung mononuclear cells from WT Mtb-infected mice were incubated with brefeldin A for four hours at 37uC and then stained. iNKT
cells were identified as TCRb+ and CD1d-tetramer+. Percentage (E) and number (F) of iNKT cells producing GM-CSF and IFNc. (G) % GM-CSF+, % IFNc+,
and CD69 MFI for iNKT cells transferred iv into WT or CD1d2/2 Mtb-infected hosts and iNKT cells cultured for 20 hours in basic media. Lung
mononuclear cells were treated and stained as in (E, F). Transferred iNKT cells were distinguished from host cells by eFluor 450 staining. Error bars
indicate mean 6 SEM. +P,.05, ++P,.01, +++P,.001 (unpaired Student’s t-test, GM-CSF+ versus IFNc+ for respective time points (E, F), WT versus
CD1d2/2 hosts (B, G)). **P,0.01, ***p,0.001 (One-way ANOVA with Tukey post-test (C), and Dunnet’s post-test (A, D), compared to uninfected mw).
Data are representative of or compiled from four (A, C), two (B), and three (D, G) independent experiments with three or more replicates each or two
independent experiments with 5 mice each (E, F). , MOI titration approximately 0.5:1–3:1 (A, B) and 2:1–10:1 (D).
doi:10.1371/journal.ppat.1003805.g007
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upregulated the activation markers, CD69 and CD25, and
produced IFNc. While IL-12 and IL-18 produced by infected
macrophages induced CD25 and IFNc expression by iNKT cells,
these cytokine signals were not required for iNKT cell control of
Mtb. In addition, macrophage expression of CD1d was dispens-
able for the upregulation of CD25 and only a minor factor in
promoting IFNc production, yet was essential to elicit iNKT cell
antimycobacterial activity.
The ability to dissociate iNKT cell activation and IFNc
production from iNKT cell antimicrobial function uncovered a
novel antibacterial function of iNKT cells: GM-CSF production.
We showed that CD1d-mediated activation was crucial for the
production of GM-CSF in response to Mtb infection by both
murine and human iNKT cells in vitro, and by murine iNKT cells
in vivo. In the absence of IFNc, GM-CSF was essential for iNKT
cell mediated inhibition of Mtb growth, and GM-CSF alone was
sufficient for bacterial control in vitro. Interestingly, under
conditions where either CD1d signaling or GM-CSF was blocked
during iNKT cell co-culture there was still on average a 30%
reduction in CFU. In the case of antibody blocking, inefficient
inhibition during the five day assay may be a technical
confounder. In addition, this data points to two alternative
biological explanations. First, signals apart from TCR activation
may contribute to the production of GM-CSF by iNKT cells
(Figure 7B). Cytokines such as IL-12 plus IL-18 stimulate iNKT
cells to produce GM-CSF (data not shown). Second, there may be
molecules other than GM-CSF and IFNc that are produced by
iNKT cells and activate infected macrophages to inhibit bacterial
growth. While GM-CSF is unlikely to be the only iNKT cell
effector function that inhibits Mtb replication, our experiments
demonstrate that it is a dominant antimicrobial pathway during
Mtb infection.
Although signaling by IFNc is crucial for control of Mtb, clinical
data shows that IFNc present at the site of ongoing infection is
inadequate to clear bacteria and IFNc levels produced by CD4+ T
cells do not correlate with disease progression or protection
provided by BCG vaccination [38,39,40]. An implication of these
studies is that alternative pathways exist that control Mtb. A
number of studies have demonstrated IFNc-independent mecha-
nisms of control by CD4+ and CD8+ T cells [41,42,43]. Using
iNKT cells as a model, we evaluated IFNc-independent pathways
of control in the innate immune compartment.
Two previous studies find GM-CSF to be required for host
resistance in vivo based on the greater susceptibility of GM-CSF2/
2 mice compared to WT mice [44,45]. Although alveolar
macrophages and type II epithelial cells were presumed to be
the dominant source of GM-CSF in the lung, ectopic expression of
GM-CSF driven by the surfactant C promoter did not fully rescue
the susceptibility of GM-CSF2/2 mice, suggesting that GM-CSF
from other sources might be important for immunity. T cells are
an important source of GM-CSF, and in addition to iNKT cells,
other innate-like T cells produce GM-CSF during Mtb infection
(manuscript in preparation). We have also found that conventional
CD4+ T cells in the lungs of Mtb infected mice produce GM-CSF
and may replace innate lymphocytes as a source of GM-CSF as
the immune response to Mtb evolves. This may be one
explanation for why iNKT cells are redundant during Mtb
infection. Although GM-CSF restricts bacterial replication in
human macrophages, its role as an effector molecule during
clinical infection is harder to discern. Importantly, recent clinical
data indicates that the development of anti-GM-CSF neutralizing
antibodies are a form of acquired immunodeficiency associated
with cryptococcal meningitis and pulmonary tuberculosis in
otherwise normal individuals [46]. This suggests that inhibition
of GM-CSF signaling may increase clinical susceptibility to Mtb
and other pulmonary pathogens.
To put our in vitro experiments in context, cytokines induced by
Mtb-infected macrophages, which include IL-12 and IL-18, are
drivers of IFNc and other cytokine production by iNKT cells,
independent of TCR activation (e.g., in an antigen-independent
manner). An important question is whether this mechanism is
relevant in vivo. In vitro, our assays use numerous macrophages
that are uniformly infected, with the consequence that the effective
cytokine concentration that the iNKT cells are exposed to could
be higher than is relevant in vivo. Furthermore, the iNKT cell
lines are primed to produce IFNc because they have been
repeatedly stimulated in vitro with aGalCer (see below). Interest-
ingly, the iNKT cell lines produced both IFNc and GM-CSF after
short-term adoptive transfer into Mtb-infected mice, but only in a
CD1d-dependent manner. Cytokine production was only ob-
served when the iNKT cells were transferred into Mtb-infected
WT mice but not when transferred into infected CD1d2/2 mice.
Thus, although CD1d-independent GM-CSF and IFNc was
observed in vitro, TCR signaling is crucial in vivo during infection
to stimulate iNKT cells to produce cytokines.
After a strong stimulus such as aGalCer, human iNKT cell
clones produce both GM-CSF and IFNc; in contrast, GM-CSF
dominates after a weak or autoreactive stimulus [47]. GM-CSF
production by iNKT cells plays an important role in the
maturation of DC, which has been linked to effective T cell
priming [47,48]. Wang et al found that in resting human iNKT
cells the CSF2 (GM-CSF) locus already had high histone H4
acetylation, indicative of chromatin availability, while the IFNG
(IFNc) locus had low histone H4 acetylation, which was increased
only after strong stimulation [34]. In contrast to the iNKT cell
lines, we observed that endogenous polyclonal iNKT cells in the
lungs of Mtb-infected mice more frequently produced GM-CSF
than IFNc, consistent with the idea that iNKT cells are poised to
produce GM-CSF more readily than IFNc, particularly when
exposed to weak TCR agonists. This study further confirms that
different iNKT cell effector functions may require different stimuli
Figure 8. GM-CSF is sufficient for inhibition of Mtb growth. CFU
assay for H37Rv-infected murine WT mw treated with recombinant GM-
CSF from 0.001–10 ng/ml concentration on d1. Error bars indicate mean
6 SEM. *P,.05, **P,0.01 (One way ANOVA with Dunnet’s post-test,
compared to d5 untreated mw). Data are representative of four
independent experiments.
doi:10.1371/journal.ppat.1003805.g008
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and that epigenetic modifications may explain at least part of this
phenomenon.
It is clear that there is great heterogeneity in iNKT cell
responses and that part of this variability comes from the diversity
in activating stimuli iNKT cells encounter. We observed two
distinct modes of activation that initiated different effector
functions: (1) the IL-12/IL-18 pathway activated iNKT cells to
produce IFNc, and (2) a TCR-dependent pathway elicited
antimycobacterial activity. Interestingly, in the context of Mtb
infection, the conventional markers of iNKT cell activation did not
correlate with effector function and our data indicate that GM-
CSF production may be a better marker of TCR-dependent
iNKT cell effector function than IFNc. Using transcriptional
profiling, Cohen et al elegantly showed that iNKT cells share
features of both NK cells and T cells [49]. Here we show that
during the host response to infection, different stimuli may trigger
different iNKT cell effector programs characteristic of NK cells
(e.g. activation by IL-12 and IL-18) or T cells (e.g. TCR
activation). Future insight into iNKT cell immunity will require
better understanding of how different activation stimuli can dictate
subsequent effector functions and may facilitate the discovery of
other novel antimicrobial roles for iNKT cells.
Materials and Methods
Ethics statement
All mice were bred and maintained using standard humane
animal husbandry protocols. All animal experiments were
performed in accordance with relevant guidelines for the care
and handling of laboratory animals and were approved by the
Dana Farber Cancer Institute Animal Care and Use Committee
(Animal Welfare Assurance number A3023-01) under Public
Health Service assurance of the Office of Laboratory Animal
Welfare guidelines. Human blood collected from healthy donors
was purchased from Research Blood Components (Boston, MA),
and its use was approved by the Institutional Review Board of
Brigham and Women’s Hospital (Human Subjects Assurance
FWA00000484). Written informed consent was obtained for each
donor by Research Blood Components.
Mice
C57Bl/6 WT, IFNc2/2, IFNcR2/2, TNFR1/22/2, Per-
forin2/2, and Fas2/2 mice were obtained from Jackson Labora-
tories. Va14-Ja281 transgenic mice were provided by Dr. Albert
Bendelac [50]. CD1d2/2 mice were provided by Dr. Mark Exley
[51]. MyD882/2 mice were provided by Dr. Koichi Kobayashi
[52].
Macrophage isolation and culture
Thioglycollate (TGL)-elicited peritoneal macrophages were
lavaged 4–5 days after 3% intraperitoneal TGL injection and
then isolated by positive selection with CD11b microbeads and
magnetic columns (Miltenyi Biotec). Purified cells were over 95%
F4/80+ CD11b+, as determined by flow cytometry. Bone marrow-
derived macrophages (BMDM) were differentiated from bone
marrow after 7 days in RPMI supplemented with 20% L929 cell
supernatant. U937 cell line was grown in complete media.
Macrophages were seeded at 56105 cells/well in 24-well culture
plates or 16105 in 96-well culture plates in complete RPMI 1640
medium (Invitrogen Life Technologies) supplemented with 10%
fetal calf serum (HyClone). For transwell assays, macrophages
were seeded at 26105 in 0.4 mm cell culture inserts for 24-well
plates (BD Bioscience).
iNKT cells and HMNC
iNKT cell lines were derived as previously reported [53]. T cells
were selected from splenocytes using the Pan T Isolation Kit
(Miltenyi Biotec) and then cultured overnight at 37uC. The next
day, T cells were labeled with PE-conjugated CD1d tetramer
loaded with PBS-57 lipid antigen (National Institutes of Health
Tetramer Core Facility) and sorted using anti-PE beads (Miltenyi
Biotec). The purity of iNKT cells was higher than 95%. iNKT
cells were then cultured with irradiated aGalCer-pulsed BMDCs
in 24-well plates in complete RPMI medium with 10% FBS.
Three to four days later, 1 ng/ml IL-2 (R&D Systems) and 10 ng/
ml IL-7 (PeproTech) were added. iNKT cells were rested for at
least 18 days before use. Human iNKT cell clones were derived
and cultured as previously described [7]. Hepatic mononuclear
cells (HMNCs) were isolated from mouse liver perfused with PBS
and homogenized through 70 um cell strainer to single cell
suspension. After centrifugation, the cells were resuspended in
30% Percoll and overlayed onto 80% Percoll layer (Sigma). The
interface containing the lymphocytes was collected and washed
before use.
Mtb in vitro culture and infection
H37Rv was grown and prepared as previously described [18].
Bacteria was counted and added to macrophages at an effective
multiplicity of infection (MOI) of 0.2 for CFU experiments (or
higher for ELISA and FACS assays) for two hours. Cultures were
washed three times to remove extracellular bacteria. Infected
macrophages were cultured overnight and iNKT cells or other
conditions were added on d1. For CFU measurement, cells were
lysed with 1% Triton X-100/PBS and lysate from quadruplicate
conditions were plated in serial dilutions on Middlebrook 7H10
agar plates (ThermoFisher Scientific), and cultured at 37uC for 21
days. Infected macrophages were treated with the following
reagents: caspase-3 inhibitor and caspase inhibitor negative
control (Calbiochem), anti-mouse-IL-12p40 (C17.8; Biolegend),
anti-mouse-IL-18 (93-10C; MBL), anti-mouse-CD1d (19G112.2)
[54], anti-human-CD1d (CD1d42; BD Pharmingen), anti-mouse-
GM-CSF (MP1-22E9; Biolegend), recombinant murine GM-CSF
(Peprotech), and IFNc (murine, Peprotech; human, Biolegend).
aGalCer was kindly provided by Gurdyal S. Besra.
% CFU reduction
To compare inhibition of bacterial growth across multiple
experiments, % CFU reduction was calculated. 100% CFU
reduction on d5 indicates complete inhibition of bacterial growth
to d1 levels while 0% CFU reduction indicates no change in
bacterial growth from untreated macrophages. % CFU reduc-
tion = 1006[CFU(untreated mf-d5)2CFU(treated mf-d5)]/[(CFU(untreated mf-
d5)2CFU(untreated mf-d1)]
In vivo aerosol infections
In vivo infections were performed using virulent Mtb (Erdman
strain). Mice infected with Mtb were housed under BSL3
conditions. For each infection, a bacterial aliquot was thawed,
sonicated twice for 10 s, and then diluted in 0.9% NaCl/0.02%
Tween 80. A 15-ml suspension of M. tuberculosis was loaded into a
nebulizer (MiniHEART nebulizer; Vortran Medical Technology)
and mice were infected via the aerosol route with a nose-only
exposure unit (Intox Products) and received ,50–100 CFU/
mouse. Mice were euthanized by CO2 inhalation and lungs were
aseptically removed after perfusion of 10 ml of sterile RPMI into
the right ventricle of the heart. Lung mononuclear cells were
obtained by mechanical disruption using a gentleMACS disso-
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ciator (Miltenyi Biotec) followed by incubation in collagenase
(Sigma-Aldrich) for 30 mins at 37uC. Cells were isolated by forcing
suspensions through a 70 mM cell strainer and then enumerated in
4% trypan blue with a hemacytometer. Samples used for ICS were
incubated for 4 hours at 37uC with IL-2 and Brefeldin A
(GolgiPlug, BD Biosciences).
Adoptive transfer of iNKT cell lines
3–56106 iNKT cells were stained with Cell Proliferation Dye
eFluor 450 (eBioscience) following the manufacturer’s protocol and
then iv injected via tail vein into Mtb-infected WT or CD1d2/2
mice. Twenty hours later, mice were euthanized and lungs were
removed and digested. Lung mononuclear cells were stained by
surface and ICS protocols and paraformaldehyde fixed. Untrans-
ferred iNKT cells cultured in standard media were similarly treated
to ascertain baseline activation. Flow cytometry gating strategies
allowed for separation of endogenous versus transferred iNKT cells
independent of tetramer staining by the presence of fluorescent dye.
Flow cytometry and ICS
Cells were first incubated with CD16/CD32 (FcBlock; BD
Biosciences). Surface staining for in vitro experiments included
antibodies for mouse CD69 (H1.2F3), CD25 (PC61), F4/80
(BM8), CD1d (1B1), and isotype controls (all from Biolegend).
Surface staining of lung mononuclear cells included antibodies for
mouse TCRb (H57-597), CD69, CD3 (17A2), CD19 (6D5) and
isotype controls (all from Biolegend). PBS-57-loaded and control
PE- and APC-conjugated CD1d tetramers were provided by the
National Institute of Allergy and Infectious Diseases Tetramer
Facility (Emory University Vaccine Center). After tetramer
staining, ICS with antibodies specific for mouse GM-CSF (MP1-
22E9; eBioscience) and IFNc (XMG1.2; Biolegend) was per-
formed following fixation with 4% paraformaldehyde and
permeabilization with Perm/Wash buffer (BD Biosciences). Data
were collected using FACSCanto (BD Biosciences) and analyzed
with FlowJo (Tree Star, Inc.).
ELISA, nitric oxide, and Bioplex immunoassays
Culture supernatants were filtered through 0.2 mm filter to
remove any bacteria. IFNc, IL-12p40, and GM-CSF ELISAs were
done in accordance with the manufacturer’s instructions (Biole-
gend), and absorbance was recorded at 450 nm on SoftMax Pro
ELISA analysis software (Molecular Devices). Nitric oxide (NO)
production was measured using the Griess reaction to detect
nitrite, a stable breakdown product of NO, as described previously
[18]. For size fractionation, Amicon Ultra-15 Centrifugal Filter
Units with 10 kDa and 50 kDa cutoff were used (EMD Millipore).
Bioplex immunoassay was done in accordance with the manufac-
turer’s instructions (BioRad).
Statistical analysis
Data was analyzed by one-way ANOVA (95% confidence
interval) with Dunnett’s post-test (for comparison against a single
control) or Tukey post-test (for comparison between all conditions)
or unpaired Student’s t-test. Analysis was performed using
GraphPad Prism software.
Supporting Information
Figure S1 iNKT cell activation after Mtb infection is
observed with primary iNKT cells and bone marrow
derived-macrophages (BMDM). (A) HMNC were cultured
either alone, with uninfected thioglycollate-elicited peritoneal mw
(TGL-PM), or H37Rv-infected TGL-PM for 24 hours and gated on
CD1d-tetramer+CD3+ population. Fold change in CD69 MFI
measured over HMNC cultured alone. Supernatant was harvested
at 24 hours and IFNc measured by ELISA. (B) iNKT cells were
cultured with uninfected or H37Rv-infected WT bone marrow
derived macrophages (BMDM) for 24 hours. Fold change in CD69
MFI over iNKT cells cultured alone. Supernatant was harvested at
24 hours and IFNc measured by ELISA. Error bars indicate mean
6 SEM. The data is from a single experiment. Note that the IFNc
release is less than in Figure 1. This difference is likely to arise from
the use of primary HMNCs in Figure S1A and different APCs in
Figure S1B. Figure S1A uses hepatic mononuclear cells (HMNC), as
a source of primary uncultured iNKT cells, to demonstrate that the
culture conditions of the primary iNKT cell lines did not alter the
behavior of the cells. iNKT cells are a small fraction of conventional
T cells in most sites of the body. In the liver, iNKT cells make up
about 10–20% of the total lymphocytes; therefore, the difference in
the magnitude of the IFNc response may be due to the use of a
lower number of iNKT cells. Secondly, the use of cultured iNKT
cells (in Fig. 1) may generate a stronger response because they act as
if ‘primed’ because they are repeatedly stimulated in the presence of
cytokines. Fig. S1B used BMDM to show that Mtb-infected APCs
other than TGL-PM stimulate iNKT cells. BMDM are not as
activated as TGL-PM, which contributes to the difference in the
level of responses in this experiment.
(EPS)
Figure S2 WT and IFNc2/2 iNKT cells both inhibit Mtb
growth in vitro at comparable levels. Compiled data from
CFU assays d5 and d7 post-infection for H37Rv-infected WT mw
with WT or IFNc2/2 iNKT cells added on d1. The CFU reduction
for WT and IFNc2/2 iNKT cells on d5 was 60.064.7%, and
60.164.0%, respectively. On d7, the CFU reduction was
81.965.4%, and 67.966.2%, respectively. Error bars indicate
mean 6 SEM. (Unpaired Student’s t-test, p = NS). The data are
compiled from 13 (d5) and four (d7) independent experiments.
(EPS)
Figure S3 Conditioned media fractions from a-GalCer
stimulated IFNc2/2 iNKT cells inhibit bacterial growth.
(A) Size fractionation strategy for conditioned media samples using
50 kDa and 10 kDa Amicon Ultra-15 Centrifugal Filter Units. (B)
CFU assay for H37Rv-infected WT mw treated on d1 with whole
and size fractionated conditioned media samples from IFNc2/2
iNKT cells stimulated for 24 hours with untreated or aGalCer-
loaded WT or CD1d2/2 mw at 1:50 dilution. (C) Cytokines
measured in whole and size fractionated conditioned media
samples from IFNc2/2 iNKT cells stimulated for 24 hours with
untreated or aGalCer-loaded WT or CD1d2/2 mw. Cytokines
were measured using Bioplex immunoassay. Error bars indicate
mean 6 SEM. *P,0.05, **P,0.01 (One-way ANOVA with
Dunnet’s post-test, compared to d5 untreated mw). The data are
representative of two independent experiments.
(EPS)
Figure S4 WT iNKT cells produce GM-CSF following
Mtb infection. Murine GM-CSF measured in supernatants after
24-hr co-culture of WT iNKT cell line with uninfected and
H37Rv-infected WT mw. ***P,0.001 (One-way ANOVA with
Dunnet’s post-test, compared to uninfected mw). The data are
representative of three independent experiments.
(EPS)
Figure S5 Control of intracellular Mtb replication by
WT iNKT cells in the presence of anti-GM-CSF blocking
antibody. WT iNKT cells were added to H37Rv-infected WT
mw on d1 without additives, or in the presence of anti-GM-CSF
iNKT Cell Production of GM-CSF Controls Mtb
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blocking antibody or nonspecific isotype control antibody (25 mg/
ml). CFU were determined on d5. The data are compiled from
three independent experiments with four replicates per condition,
and normalized to calculate the percent CFU reduction. Statistical
analysis was performed using a one-way ANOVA and was not
significant. Error bars indicate mean +/2 SEM.
(EPS)
Figure S6 iNKT cells are found in the lung after aerosol
Mtb infection. Lung mononuclear cells from WT Mtb-infected
mice were stained and fixed. iNKT cells were identified as TCRb+
and CD1d-tetramer+. Number (A) and percentage (B) of iNKT
cells in the lung were measured. (C) CD69 MFI measured on
iNKT cell subset. The data are representative of two independent
experiments with 5 mice each.
(EPS)
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